Charles Simone
2024-10-13
Disease
REG001-09
Abatary Discription
We have previously requested all data of patients with chordoma and sarcoma receiving proton therapy from the REG001-09 study. We published the results of our chordoma analysis in 2023 (Radiother Oncol. 2023 Jun;183:109551. doi: 10.1016/j.radonc.2023.109551. PMID: 36813169), but the number of cases and follow-up were limited for other sarcomas. We would please like to have an updated data pull of these other sarcoma cases so that we could perform analyses on patients with extremity sarcomas and retroperitoneal sarcomas receiving proton therapy. We will assess patterns of care and proton doses used, acute and late toxicities, tumor control rates (local, regional, distant), progression free survival, and overall survival of these two cohorts.